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Tumour hypoxia is a microenvironmental factor related to poor response to radiation, chemotherapy, genetic instability, selection for
resistance to apoptosis, and increased risk of invasion and metastasis. Hypoxia-regulated carbonic anhydrase IX (CA IX) has been
studied in various tumour sites and its expression has been correlated with the clinical outcome. The purpose of this study was to
investigate the correlation of CA IX expression with outcome in patients with invasive breast cancer. We conducted a retrospective
study examining the effects of carbonic anhydrase IX (CA IX) on survival in patients with breast cancer. To facilitate the screening of
multiple tissue blocks from each patient, tissue microarrays were prepared containing between two and five representative samples
of tumour per patient. Immunohistochemistry was used to examine expression of CA IX in patients with breast cancer. The study
includes a cohort of 144 unselected patients with early invasive breast cancer who underwent surgery, and had CA IX expression and
follow-up data available for analysis. At the time of analysis, there were 28 deaths and median follow-up of 48 months with 96% of
patients having at least 2 years of follow-up. CA IX was negative for 107 patients (17 deaths) and positive for 37 patients (11 deaths).
Kaplan–Meier survival curves show that survival was superior in the CA IX-negative group with a 2-year survival of 97% for negatives
and 83% for positives (log-rank test P¼0.01). Allowing for potential prognostic variables in a Cox regression analysis, CA IX
remained a significant independent predictor of survival (P¼0.035). This study showed in both univariate and multivariate analysis
that survival is significantly inferior in patients with tumour expressing CA IX. Prospective studies are underway to investigate this
correlation in clinical trial setting.
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Breast cancer represents a major public health problem, with more
than 1000000 new cases and 370000 deaths yearly worldwide.
Despite pivotal developments in endocrine therapy and chemo-
therapy, resistance to therapy remains a key limitation in the
management of invasive breast cancer. A fundamental difficulty in
the understanding, prevention, and treatment of breast cancer is
clinical heterogeneity between tumours. This is commonly
manifested as variable responses to specific therapeutic regimens.
Numerous studies indicate that this clinical heterogeneity reflects
underlying molecular heterogeneity. Tumour hypoxia is a micro-
environmental factor related to poor response to radiation and
chemotherapy, genetic instability, selection for resistance to
apoptosis, and increased risk of invasion and metastasis (Brizel
et al, 1996; Graeber et al, 1996; Hockel et al, 1996; Reynolds et al,
1996; Kim et al, 1997). Tumour hypoxia has been studied in a
variety of solid tumours and has been correlated with clinical
outcome often using invasive monitoring of tissue oxygenation
(Hockel et al, 1994; Brizel et al, 1995; Nordsmark et al, 1996; Fyles
et al, 1998; Knocke et al, 1999; Fyles et al, 2002). Hypoxia has also
been shown to have a prognostic impact in patients with breast
cancer, head and neck cancer, and soft tissue sarcomas. The
hypoxia-regulated protein carbonic anhydrase IX, CA IX, has been
studied in various tumour sites and its expression has been
correlated with clinical outcome (Chia et al, 2001; Loncaster et al,
2001; Kaanders et al, 2002; Swinson et al, 2003; Hussain et al,
2004). Carbonic anhydrase IX expression and its correlation with
tumour oxygen measurements have previously been reported
(Loncaster et al, 2001) and contradicted (Mayer et al, 2005).
Hypoxia results in the upregulation of genes that facilitate
anaerobic metabolism and promote tumour vascularisation (e.g.
vascular endothelial growth factor, VEGF). Carbonic anhydrase IX
is induced by hypoxia in a range of tumour cell lines in an
hypoxia-inducible factor-1 (HIF-1)- dependent manner (Wykoff
et al, Cancer Research, 2000), its role being to regulate tissue pH
(Svastova et al, FEBS Lett, 2004). Studies have directly and
indirectly validated the use of CA IX, as an intrinsic surrogate
marker of hypoxia (Loncaster et al, 2001; Turner et al, 2002;
Hoskin et al, 2003). In order to understand the contribution of
hypoxia to tumour progression, resistance to treatment, and, in the
future, to exploit differential expression of hypoxia-related factors
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sin tumours vs normal tissue for therapeutic gain, we have
examined the expression of CA IX in breast cancer and related
this to clinico-pathological parameters and clinical outcome.
MATERIALS AND METHODS
The study consists of 144 unselected patients with early invasive
breast cancer who underwent surgery at the Queen Elizabeth
Hospital Birmingham for which CA IX and follow-up data were
available. To facilitate the screening of multiple tissue blocks from
each patient, tissue arrays were prepared.
Tissue microarray construction
Haematoxylin and eosin (H&E) sections from each case were
screened by a pathologist and appropriate representative areas of
tumour highlighted for sampling. Tissue cores for the construction
of tissue microarrays (TMAs) were taken with a 3-mm skin punch
biopsy needle (Stiefel Laboratories, UK) from the paraffin blocks
that were used for histological diagnosis. The tissue cores were
inserted in the holes of the rectangular carrier made of liver tissue,
punched out by a 4-mm punch biopsy needle (Stiefel Laboratories,
UK). The carrier facilitated the smooth cutting of sections with
minimal artefacts in transition from paraffin to tissue.
Each carrier had a grid of 4 5 holes and, in addition to the
breast tumour tissue samples, contained one core of normal breast
tissue as a control. Four cores per sample, from multiple areas of
the same tumour, were included in the TMA and embedded in
different blocks at different positions on the grid for redundancy.
After core insertion, tissue was re-embedded in paraffin. A small
number of cores were damaged during TMA construction or
subsequent methods and were labelled as noninformative. On an
average, 83.4% of the cores, or 3.3 cores per specimen, were
informative and were used in the analysis. (Murray et al, 2003;
Tsoli et al, 2006).
Immunohistochemistry
Sections 4mM were cut from each array block onto charged slides
(Surgipath, UK) and heated for 1h at 601C. After deparaffinising
and rehydration, sections were treated in 0.3% H2O2 in water to
block endogenous peroxidase activity. Antigen retrieval was
performed using the ALTER technique as previously described
(Reynolds et al, 2002) in ethylene diamine tetraacetic acid (EDTA)
buffer with Tween 20 overnight at 651C. Following a brief wash in
water, sections were placed onto a Sequenza (Shandon, UK) and
washed in TBS (pH 7.6). A mouse monoclonal antihuman antibody
(M75) raised to the external domain of CA IX (Pastorekova et al
1992) was applied at 1/100 dilution for 1h (Table 1). After washing
in TBS/Tween, primary antibody was visualised using Dako
ChemMate Envsion detection kit (Dako, UK Ltd, Cat no. K5007)
and Vector NovaRed chromagen (cat No SK-4800, Vector
Laboratories, UK). Sections were then counterstained in haema-
toxylin, washed in water, rapidly dehydrated, placed into xylene
and mounted in DPX. Negative controls consisted of sections
processed in the same way but with omission of the primary
antibody step.
Evaluation of staining
Evaluation of immunostaining was performed on two separate
occasions by one observer (SAH) and once by a pathologist (RG),
both of whom were blinded to any other data. The whole of each
section was subjectively assessed under light microscopy. For
assessment of the level of CA IX expression, individual tumours
were scored according to the level of staining in tumour cells.
Staining of the biliary epithelial cells within surrounding liver
(used to support the breast cores) served as the internal positive
control (unpublished data). There was one score for the strength of
staining (absent, weak, or strong, respectively) and one score for
distribution pattern within the tumour stained (absent, focal/
patchy, or diffuse). Sections where intra-observer or inter-observer
Table 1 Antibody used
Antibody Code Source Dilution
CA IX M 75
monoclonal
antibody to
MN/CAIX
Institute of virology,
Slovak, and Institute
of molecular
genetics Czech
institute
1:100
CA IX¼carbonic anhydrase IX.
Table 2 Patient demographics
Characteristic Statistic
Age
Median (IQR
a) 62 years (52–74)
Range (29–94)
Surgery type
WLE+ALNC 65 (45%)
Mastectomy 79 (55%)
Tumour size
Median (IQR) 2.2cm (1.5–3.4)
Range 0.2–15
o2cm 65 (45%)
42cm 79 (55%)
Nodal status
Positive 51 (35%)
Negative 81 (56%)
Not known 12 (8%)
Tumour grade
1 17 (12%)
2 78 (54%)
3 47 (33%)
Not known 2 (1%)
DCIS grade
Low 5 (3%)
Intermediate 26 (18%)
High 63 (44%)
Not seen 50 (35%)
Side of tumour
Left 70 (49%)
Right 72 (50%)
Not known 2 (1%)
Vascular invasion
Present 38 (26%)
Absent 106 (74%)
ER status
Positive 104 (72%)
Negative 40 (28%)
NPI
o3.4 38 (26%)
X3.4 94 (65%)
Not known 12 (8%)
aIQR-interquartile range; NPI-Nottingham Prognostic Index.
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serror occurred for either of the scores were reviewed again by a
pathologist (RG) and assigned a score that dictated which of the
two original scores was recorded. In the event of all three pairs of
scores differing, a consensus score was agreed upon after
examination by both observers (SAH and RG) at a multiheaded
microscope. Tumours were categorised into five patterns of
expression of CA IX: tumour negative, weak diffuse (WD),
weak focal (WF), strong diffuse (SD), or strong focal (SF).
Expression of CA IX, whether strong or weak and focal or diffuse
was grouped as positive.
Statistical methods
Correlations between CA IX (positive or negative) and known
prognostic variables of tumour size (numeric), tumour grade (low,
intermediate, or high), axillary lymph node status (positive or
negative), side of tumour (left or right), surgery type (mastectomy
or WLEþ ALNC), vascular invasion (present or absent), ER status
(positive or negative), DCIS grade (low, intermediate, high, or not
seen), and the Nottingham Prognostic Index (numeric score
derived from tumour size, histological grade, and axillary lymph
node status; Galea et al, 1992) were explored by using w
2 and
Fischer’s exact tests for the categorical measures and t-tests for the
numerical measures. Survival times were calculated as the date of
primary tumour diagnosis to date of death, or date of censor, if alive.
Survival curves were constructed using the method of Kaplan and
Meier (1958), and the log-rank test (Peto et al, 1977) was used to
assess any differences in survival time between levels of CA IX and
levels of other known prognostic factors. Cox regression analysis was
used to assess the association of CA IX with survival time alongside
the other potential prognostic factors in a multivariate setting (Cox,
1972), with Wald tests used to report statistical significance of
factors. Statistical analysis was carried out independently using SAS
statistical software (SAS Institute, Cary, NC, USA).
RESULTS
Patient demographics
The clinico-pathological demographics of the 144 women in this
study are summarised in Table 2. Of these women, 131 (91%) had
Figure 1 Carbonic anhydrase IX immunohistochemistry. (A) Weak focal staining. Some tumour cells are unstained (single arrow), while others show
weak CA IX staining of cell membranes (block arrow) (magnification  20). (B) Weak diffuse staining. All tumour cells show CA IX staining but the intensity
is weak ( 20). (C) Strong focal staining. Groups of cells in the centre of tumour islands staining strongly on the cell membrane (block arrows) ( 20). (D)
Strong focal staining. Some groups of tumour cells stain strongly (block arrows), while other areas of tumour show no staining (single arrow) ( 40). (E)C A
IX staining is membranous ( 40). (F) Normal breast ducts and lobules do not stain with CA IX antibody ( 20).
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scomplete clinical data. Of particular note, the median age was 62
years, median tumour size was 2.2cm, the proportion with positive
axillary lymph nodes was 35%, and the proportion with ER-
positive tumours was 72%. Carbonic anhydrase IX expression was
detected in 37 of 144 cases (26%) (Figure 1) Expression of CAIX
was always seen at the cell membranes. The distribution of this
positive expression was largely in solitary or disparate foci of the
examined tissue and was categorised as focal (Table 3).
Correlation between CA IX expression and
clinico-pathological features
There was no evidence that CA IX expression was associated with
known prognostic variables, specifically tumour size (P¼0.13),
DCIS grade (P¼0.89), axillary lymph node status (P¼0.38), and
ER status (P¼0.11), side of tumour (0.50), surgery type (P¼0.13),
vascular invasion (P¼0.59), tumour grade (0.40), and Nottingham
Prognostic Index (P¼0.39).
Correlation between CA IX expression and survival
At the time of analysis, 28 of the 144 patients had died (17 and 11
in the CA IX negative and positive, respectively). Median follow-up
for the alive patients was 48 months (range 5–71 months), with
96% having at least 2 years follow-up. In a univariate analysis, the
data showed some evidence for vascular invasion, ER status,
Nottingham Prognostic Index (NPI), and tumour grade to be
prognostic for survival, although not all at a statistically significant
level, possibly owing to the relatively small size of the study
(Table 4). Survival was superior for the CA IX-negative tumours
compared with CA IX positive (Figure 2), with a 2-year survival
rate of 97 and 83% for CA IX-negative and -positive tumours,
respectively. The hazard of death for patients with CA IX-positive
tumours was approximately two and half times that for negatives
(hazard ratio (HR)¼ 2.63; 95% confidence interval (CI) 1.21–5.70;
log-rank P¼0.01). In a Cox regression analysis, based on the 133
patients with complete data, even after adjusting for the NPI, CA
IX remained significantly associated with survival (P¼0.03). In
fact, when adjusting individually for any of the prognostic
variables in Table 1, CA IX always remained significantly
associated with survival. Using the procedure of forwards stepwise
selection and a significance level of 5% for inclusion of a variable
in a model, it was found that the model best fit for accurately
describing the variability in survival time should include the
variables of vascular invasion (HR¼2.33; 95% CI 1.01–5.56;
P¼0.049) and CA IX marker status (HR¼2.43; 95% CI 1.07–5.53;
P¼0.035). The remaining variables of tumour size, tumour grade,
nodal status, surgery type, ER status, and NPI did not reach the
level of statistical significance required for inclusion in the model.
DISCUSSION
Recent studies have demonstrated that many human tumours are
hypoxic. This is likely to be due to compromised micro-circulation
within a tumour. The clinical importance of tumour hypoxia is its
association with a more aggressive malignant phenotype, increased
risk of metastasis, and resistance to chemo- and radiotherapy
(Brizel et al, 1996; Graeber et al, 1996; Hockel et al, 1996; Reynolds
et al, 1996; Kim et al, 1997).
Carbonic anhydrase IX is induced by hypoxia in a range of tumour
cell lines in an HIF-1-dependent manner (Wykoff et al, Cancer
Research, 2000), its role being to regulate tissue pH (Svastova et al,
FEBS Letters, 2004). Studies have directly and indirectly validated the
use of CA IX as an intrinsic surrogate marker of hypoxia (Loncaster
et al 2001; Turner et al, 2002; Hoskin et al, 2003).
In this study, we report that 37 of 144 unselected cases of
invasive breast cancer express CA IX. Importantly, CA IX
expression was not detected in normal breast tissue. Carbonic
anhydrase IX expression was associated with a worse prognosis,
even when controlling for other known prognostic factors.
These data are in general agreement with those published by
Chia et al (2001). In that series of 103 women with breast cancer,
CA IX was expressed in 48% of cases and was significantly
associated with ER negativity, higher tumour grade and tumour
necrosis. Multivariate analysis showed CA IX to be an independent
predictor of overall survival with a HR of 2.61 (1.01–6.75).
Similarly, another study (Vaupel et al, 1991) reported significant
hypoxia in six out of 15 cases assessed by invasive computerised
oxygen tension measurements.
In our series, the percentage of CA IX-positive tumours was
lower (26%). This may be due, in part, to heterogeneity in CA IX
staining both within and between individual tumours, which might
lead to inaccuracy in estimating the number of positive and
negative tumours. Additionally, this may be related to differences
in technique and interpretation in nonstandardised immuno-
histochemistry assays. It was interesting to note that when
adjusted individually for any of the prognostic variables, vascular
invasion and CA IX expression always remained significantly
associated with survival and the HR from our multivariate analysis
was comparable to that found by Chia et al.
Hypoxia is reported to be an adverse prognostic factor in most
human tumours. This study demonstrates that 26% of breast
Table 3 CA IX expression
CA IX staining Patient number
Strong diffuse 0
Strong focal 13
Weak diffuse 1
Weak focal 23
Negative 107
CA IX¼carbonic anhydrase IX.
Table 4 Univariate analysis of potential prognostic factors for survival
Hazard
ratio
95% Confidence
interval
P-value from
log-rank test
Surgery type
Mastectomy vs WLE 1.19 0.53–2.65 0.67
Tumour size
X2 vs o2cm 2.41 0.95–6.12 0.06
Nodal status
Positive vs negative 1.42 0.63–3.22 0.40
Tumour grade
3 vs 1, 2 1.80 0.80–4.02 0.15
Side of tumour
Right vs left 1.16 0.52–2.57 0.71
Vascular invasion
Present vs absent 2.56 1.11–5.89 0.03
ER status
Positive vs negative 0.47 0.21–1.05 0.07
NPI
X3.4 vs o3.4 2.39 0.82–6.99 0.11
CA IX
Positive vs negative 2.63 1.21–5.70 0.01
CA IX¼carbonic anhydrase IX; NPI¼Nottingham Prognostic Index.
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scancers are positive for CA IX expression. This information may
have prognostic value in that CA IX expression is a predictor of
poorer survival independently of other recognised prognostic
factors. This information may, therefore, facilitate a more refined
selection of patients for adjuvant treatment. By adding to
established prognostic factors, CA IX expression may contribute
to the identification of patients at greater risk of relapse who
should be offered adjuvant treatment while sparing those whose
prognosis is already good.
At the time of diagnosis for the patients in this series,
Her-2 testing was not routinely performed. Thus, correlations
between CA IX expression and Her-2 could not be made. Because
of the prognostic importance of Her-2, this question must be
addressed in future prospective studies in patients with known
Her-2 status.
Furthermore, as hypoxia is related to resistance to chemo-
therapy and radiotherapy, CA IX expression may serve as a predictive
factor to guide the selection of the most appropriate adjuvant
treatment modality. Moreover, as hypoxia as a cause of treatment
resistance can be effectively overcome by a variety of strategies,
including high-oxygen-content gas breathing, blood transfusion,
haemoglobin–oxygen affinity modifiers, and nicotinamide, the
incorporation of these could be further investigated in patients
with breast cancer.
Finally, the expression of CA IX in a number of breast tumours
examined in this study, compared to the absence of CA IX in
normal breast tissue, indicates that hypoxia and hypoxia-related
gene expression may present a useful target for novel targeted
therapies, for example drugs or gene therapy vectors that are
specifically activated under hypoxic conditions. This study
provides a rationale basis for the further study of these approaches
in breast cancer. Randomised studies with translational end points
are required to further elucidate the prognostic and predictive
value of CA IX. Prospective study within the context of an adjuvant
chemotherapy trial is underway to investigate and explore this
correlation in clinical trial setting.
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